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Background—Among drug-eluting stents released to date, the sirolimus-eluting stent has demonstrated the least amount
of late lumen loss, but its efficacy and safety have not been compared head-to-head with the next-generation
everolimus-eluting stent.
Methods and Results—The Scandinavian Organization for Randomized Trials with Clinical Outcome IV (SORT OUT IV)
trial was a randomized multicenter, single-blind, all-comer, 2-arm, noninferiority trial comparing the everolimus-eluting
stent with the sirolimus-eluting stent in patients with coronary artery disease. The primary end point was a composite
of safety (cardiac death, myocardial infarction, definite stent thrombosis) and efficacy (target vessel revascularization)
parameters. The noninferiority criterion was a risk difference of 0.015. Intention-to-treat analyses were done at 9- and
18-month follow-ups. A total of 1390 patients were assigned to receive the everolimus-eluting stent and 1384 patients
to the sirolimus-eluting stent. At the 9-month follow-up, 68 patients (4.9%) treated with the everolimus-eluting stent
compared with 72 patients (5.2%) treated with the sirolimus-eluting stent experienced the primary end point (hazard
ratio, 0.94; 95% confidence interval, 0.67–1.31; P for noninferiority0.01). At the 18-month follow-up, this differential
remained: 99 patients (7.2%) treated with the everolimus-eluting stent versus 105 (7.6%) treated with the sirolimus-
eluting stent (hazard ratio, 0.94; 95% confidence interval, 0.71–1.23). At the 9-month follow-up, the rate of definite stent
thrombosis was higher in the sirolimus-eluting group (2 patients [0.1%] versus 9 patients [0.7%]; hazard ratio, 0.22; 95%
confidence interval, 0.05–1.02). At the 18-month follow-up, this difference was sustained (3 patients [0.2%] versus 12
patients [0.9%]; hazard ratio, 0.25; 95% confidence interval, 0.07–0.88).
Conclusion—The everolimus-eluting stent was found to be noninferior to the sirolimus-eluting stent.
Clinical Trial Registration—URL: http://www.clinicaltrials.gov. Unique identifier: NCT00552877.
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In percutaneous coronary interventions, drug-eluting stentimplantation is used increasingly for revascularization in
patients with coronary artery disease. Compared with bare
metal stents, first-generation drug-eluting stents, such as
sirolimus- and paclitaxel-eluting stents, have shown im-
proved results, reducing the need for repeat revascularization,
as assessed in randomized trials.1–3
Although drug-eluting stents are widely accepted as effec-
tive and safe, debate continues on the safety of first-
generation drug-eluting stents, given the potential for late
stent thrombosis, especially after discontinuation of dual
antiplatelet therapy.4,5 Second-generation drug-eluting stents
were designed to improve efficacy, safety, and device per-
formance. However, the first commercially available second-
generation drug-eluting stent, the zotarolimus-eluting En-
deavor stent, did not appear superior to the sirolimus-eluting
stent in routine practice.6 The next second-generation drug-
eluting stent, the everolimus-eluting stent, proved superior to
the paclitaxel-eluting stent, with a lower rate of stent throm-
bosis, myocardial infarction, and target vessel revasculariza-
tion7 and reduced angiographic late loss.8 In a recent all-
comer trial of second-generation drug-eluting stents, the
zotarolimus-eluting stent proved noninferior to the
everolimus-eluting stent despite a higher 1-year rate of
definite stent thrombosis in the zotarolimus group.9
Clinical Perspective on p 1255
The Scandinavian Organization for Randomized Trials
with Clinical Outcome IV (SORT OUT IV) trial aimed to
compare the safety and efficacy of the first-generation
sirolimus-eluting Cypher Select stent and the second-
generation everolimus-eluting Xience V/Promus stent in a
population-based setting using registry detection of clinically
driven events.
Methods
Patients and Study Design
SORT OUT IV10 is a randomized, multicenter, single-blind, all-
comer, 2-arm, noninferiority trial comparing the everolimus-eluting
stent and the sirolimus-eluting stent in treating atherosclerotic
coronary artery lesions. The study period was August 2007 to June
2009. Danish registry data11–13 were used to compare patients
eligible for randomization who did not enroll with patients randomly
allocated to treatment (Table 1), as required by the Consolidated
Standards of Reporting Trials (CONSORT) statement.14
Eligible patients were at least 18 years of age and had chronic
stable coronary artery disease or acute coronary syndromes and at
least 1 coronary artery lesion with50% diameter stenosis requiring
treatment with a drug-eluting stent. If multiple lesions were treated,
the allocated study stent had to be used in all lesions. No restrictions
were placed on the number of treated lesions, number of treated
vessels, or lesion length. Exclusion criteria were life expectancy of
1 year; an allergy to aspirin, clopidogrel, sirolimus, or everolimus;
participation in another randomized trial; or inability to provide
written informed consent. The study complied with the Declaration
of Helsinki and was approved by the local ethics committee. All
patients provided written informed consent for trial participation.
Randomization
Patients were enrolled by the investigators and randomly allocated to
treatment groups after diagnostic coronary angiography and before
percutaneous coronary intervention. Block randomization by center
(permuted blocks of random sizes [2/4/6]) was used to assign
patients in a 1:1 ratio to receive the everolimus-eluting stent (Xience
V, Abbott Vascular, or PROMUS, Abbott’s privately labeled Xience
V Everolimus Eluting Coronary Stent System distributed by Boston
Scientific Corp) or the sirolimus-eluting stent (Cypher Select,
Cordis, Johnson &Johnson). An independent organization computer
generated the allocation sequence, stratified by sex and presence of
diabetes mellitus. Patients were assigned to treatment through an
automated telephone allocation service. Although operators were
unblinded, all patients and individuals analyzing data were masked
to treatment assignment.
Study Procedures
The everolimus-eluting stent was available in 6 diameters (2.25,
2.50, 2.75, 3.00, 3.5, and 4.00 mm) and 6 lengths (8, 12, 15, 18, 23,
and 28 mm). The sirolimus-eluting stent was available in 5 diameters
(2.25, 2.50, 2.75, 3.00, and 3.50 mm) and 6 lengths (8, 13, 18, 23, 28,
and 33 mm). Stents were implanted according to standard tech-
niques. Direct stenting without prior balloon dilation was allowed.
Full lesion coverage was attempted by implanting 1 stents.
Drug-eluting stents not specified by the random allocation scheme
and bare metal stents were prohibited unless the study stent could not
be implanted. In such cases, other stents or balloon angioplasty alone
was allowed. Before implantation, patients received at least 75 mg
aspirin, a 600-mg loading dose of clopidogrel, and a dose of
unfractionated heparin dose (5000 IU or 70–100 IU/kg). Glycopro-
Table 1. Baseline Demographic and Clinical Characteristics of
Patients Who Were and Were Not Randomly Assigned to
Treatments Groups
Randomized
(n2774),
n (%)
Not Randomized
(n3952),
n (%) P
Age, mean (SD), y 64.1 (10.8) 63.5 (13.2) 0.045
Men 2098 (75.5) 2861 (72.4) 0.004
Diabetes mellitus 390/2774 (14.0) 438/2889 (15.2) 0.23
Current smoker 698/2342 (29.8) 949/2777 (34.2) 0.001
Indication for percutaneous
coronary intervention
0.001
ST-segment–elevation
myocardial infarction
267 (9.6) 1334 (33.8)
Non–ST-segment–
elevation myocardial
infarction or unstable
angina
911 (32.8) 1149 (28.8)
Stable angina 1530 (55.1) 1396 (35.3)
Other 69 (2.5) 82 (2.1)
Target lesions per patient 0.006
1 1984 (71.4) 2883 (73.0)
2 593 (21.4) 835 (21.1)
3 200 (7.2) 234 (5.9)
Treated vessels per patient 0.001
1 2247 (80.9) 3310 (83.8)
2 477 (17.2) 599 (15.2)
3 53 (1.9) 43 (1.1)
Comorbidity index score 0.018
0 1236 (44.5) 1755 (44.4)
1–2 1154 (41.6) 1553 (39.3)
3 387 (13.9) 644 (16.3)
All-cause mortality at 30 d 21 (0.8) 72 (1.8) 0.001
Source: Western Denmark Heart Registry.
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tein IIb/IIIa inhibitors were used at the operator’s discretion. Rec-
ommended postprocedural dual antiplatelet regimens were 75 mg
aspirin daily lifelong and 75 mg clopidogrel daily for 1 year.
End Points
The primary end point was a combination of safety (cardiac death,
myocardial infarction, definite stent thrombosis) and efficacy (clin-
ically indicated target vessel revascularization) parameters within 9
months of stent implantation. Intention-to-treat analyses were con-
ducted after 9 and 18 months of follow-up. Individual components of
the primary end point comprised the secondary end points: cardiac
death rate; myocardial infarction rate; definite stent thrombosis rate;
rate of clinically indicated target vessel revascularization; rate of
probable, possible, and overall stent thrombosis according to the
Academic Research Consortium (ARC) definition15; symptom-
driven target lesion revascularization; and device failure (defined as
inability to implant the assigned study stent in 1 target lesions).
Definitions
The study end points were defined as follows:
● Cardiac death: any death resulting from an evident cardiac cause,
any death related to percutaneous coronary intervention, an unwit-
nessed death, or death from unknown causes.
● Myocardial infarction: the universal definition used by the Euro-
pean Society of Cardiology, American College of Cardiology,
American Heart Association, and World Heart Federation.16 Bio-
markers were not assessed at the time of the index percutaneous
coronary intervention procedure.
● Stent thrombosis: definite, probable, or possible stent thrombosis
according to the ARC15 definition.
● Target vessel revascularization: any repeat percutaneous coronary
intervention or surgical bypass of any segment within the entire
major coronary vessel that was proximal or distal to a target lesion,
including upstream and downstream branches, and the target
lesion itself.
● Target lesion revascularization: repeat revascularization caused by
a 50% stenosis within the stent or within a 5-mm border
proximal or distal to the stent. Target vessel and target lesion
revascularization were clinically driven.
● Comorbidity: For all patients, we obtained data on all hospital
diagnoses from the Danish National Registry of Patients covering
all Danish hospitals from 1977 until the implantation date.11 We
then computed Charlson Comorbidity Index score, which covers
19 major disease categories, including diabetes mellitus, heart
failure, cerebrovascular diseases, and cancer.17
Clinical Event Detection
Clinically driven event detection was used to avoid study-induced
reinterventions. Data on mortality, hospital admission, coronary
angiography, repeat percutaneous coronary intervention, and coro-
nary bypass surgery were obtained for all randomly allocated
patients from the following national Danish administrative and
healthcare registries: the Civil Registration System; the Western
Denmark Heart Registry12; the Danish National Registry of Pa-
tients,11 which maintains records on all hospitalizations in Denmark;
and the Danish Registry of Causes of Death.13 Independent event
committee members who were blinded to treatment group assign-
ment during the adjudication process reviewed all end points and
source documents to adjudicate causes of death, reasons for hospi-
talization, and diagnosis of myocardial infarction; they reviewed cine
films to classify stent thrombosis and target vessel revascularization
(with either percutaneous coronary intervention or coronary artery
bypass grafting).
The Danish National Health Service provides universal tax-
supported health care, guaranteeing residents free access to general
practitioners and hospitals. The Danish Civil Registration System
has kept electronic records on sex, birth date, residence, emigration
date, and vital status changes since 196818 with daily updates; the
10-digit civil registration number assigned at birth and used in all
registries allows accurate record linkage. The Civil Registration
System provided vital status data for our study participants and
minimized loss to follow-up. The National Registry of Causes of
Deaths and the Danish National Registry of Patients provided
information on causes of death and diagnoses assigned by the
treating physician during hospitalizations (coded according to the
International Classification of Diseases, 10th revision).11
Statistical Analysis
The trial was powered for assessing the noninferiority of the
everolimus-eluting stent to the sirolimus-eluting stent with respect to
the primary end point at 9 months. An event rate of 0.0688 was
assumed in the everolimus-eluting stent group and 0.07819 in the
sirolimus-eluting stent group, with an expected difference in event
rates between the 2 groups of 0.010 at 9 months. With a sample
size of 1339 patients in each treatment arm, a 2-group large-sample
normal approximation test of proportions with a 1-sided 0.050
significance level will have 80% power to detect noninferiority with
a predetermined noninferiority margin of 0.015. The sample size of
1339 assumes a 0% lost-to-follow-up rate given the use of the Civil
Registration System. A Farrington-Manning20 test was used to test
for noninferiority. Distributions of continuous variables were com-
pared between study groups by use of the 2-sample t test (or Cochran
test for cases of unequal variance) or the Mann-Whitney U test,
depending on whether the data followed a normal distribution.
Distributions of categorical variables were compared by use of the 2
test. In analyses of every end point, follow-up continued until the
date of an end-point event, death, or emigration or 18 months after
stent implantation, whichever came first. Survival curves were
constructed on the basis of time to events, accounting for the
competing risk of death. Hazard ratios were computed with Cox
proportional hazards regression analysis. Patients treated with the
sirolimus-eluting stent were used as the reference group for overall
and subgroup analyses. Hazard ratios were calculated for major
adverse cardiac events at the 18-month follow-up for prespecified
patient subgroups (based on baseline demographic and clinical
characteristics). The intention-to-treat principle was used in all
analyses. Except for the inferiority testing of the primary end point,
a 2-sided value of P0.05 was considered to indicate statistical
significance. Analyses were conducted with SAS software (version
9.2). This trial is registered at http://www.clinicaltrials.gov (number
NCT00552877).
Results
Patients and Enrollment
A total of 9385 patients were screened, and 2774 patients
with 3584 lesions were randomly assigned to receive either
the everolimus-eluting stent (1390 patients with 1805 lesions)
or the sirolimus-eluting stent (1384 patients with 1779 le-
sions). One patient was lost to follow-up on day 187 because
of emigration (this person was considered a success [non-
event] for the noninferiority analysis of the primary end
point). The flow diagram of the trial is provided in Figure 1.
Baseline characteristics were recorded for all patients eligible
for randomization regardless of subsequent trial participation
(Table 1). Eligible nonrandomized patients were older, were
more often hospitalized with ST-segment–elevation myocar-
dial infarction, and had higher 30-day mortality than random-
ized patients.
Baseline demographic and clinical characteristics were
well balanced between the 2 study groups (Table 2). Patients
in the sirolimus-eluting stent group had more left anterior
descending coronary artery lesions. The maximum stent
implantation pressure was higher in the sirolimus-eluting
stent group (Table 3). A high proportion of patients in both
groups had acute coronary syndromes, multivessel disease,
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and complex lesions (Table 4). A total of 194 patients
(14.0%) treated with everolimus-eluting stents had diabetes
mellitus compared with 196 patients (14.2%) treated with
sirolimus-eluting stents.
Clinical Outcomes
The composite primary end point occurred in 68 patients
(4.9%) in the everolimus-eluting stent group and in 72
patients (5.2%) in the sirolimus-eluting stent group (Figure
2). Noninferiority of the everolimus-eluting stent was estab-
lished, with a 9-month absolute risk difference of 0.3% and
the upper limit of the 1-sided 95% confidence interval at
1.1% (1-sided P for noninferiority0.02). Rates of death,
cardiac death, myocardial infarction, clinically driven target
vessel revascularization, and clinically driven target lesion
revascularization did not differ significantly between the 2
stent groups (Table 4). The result was sustained for the
composite end point at 18 months, which occurred in 99
patients (7.2%) in the everolimus-eluting stent group and in
105 patients (7.6%) in the sirolimus-eluting stent group
(Table 4 and Figure 2). Definite stent thrombosis occurred
within 9 months in 2 patients (0.1%) in the everolimus-
eluting stent group and in 9 patients (0.7%) in the sirolimus-
eluting stent group (P0.053). At the 18-month follow-up,
this difference was sustained (3 patients [0.2%] versus 12
patients [0.9%]; P0.03; Figure 2 and Table 4). (Because of
small event rates, we further tested this difference with a
Fisher exact test [P0.021].) At the 18-month follow-up,
definite or probable stent thrombosis did not differ between
the 2 groups; it occurred in 10 patients (0.7%) in the
everolimus-eluting stent group and in 16 patients (1.2%) in
the sirolimus-eluting stent group (P0.24; Table 4). Probable
stent thrombosis was caused by 7 unexplained deaths within
the first 30 days in the everolimus-eluting stent group
compared with 4 unexplained deaths within the first 30 days
in the sirolimus-eluting stent group (Table 4). Findings for the
primary end point were consistent across prespecified strati-
fied analyses (Figure 3). The primary end point did not differ
significantly between the 2 stent groups among patients with
and without diabetes mellitus. Among diabetic patients, rates
of major cardiac adverse events did not differ significantly
between the everolimus-eluting and sirolimus-eluting stent
groups at 18 months (10.3% and 15.8%, respectively; hazard
ratio, 0.63; 95% confidence interval, 0.36–1.11).
Discussion
Our trial provides the first head-to-head comparison of the
everolimus-eluting stent and the sirolimus-eluting stent (con-
sidered the most validated and efficient first-generation drug-
eluting stent). We documented noninferiority of the
everolimus-eluting stent overall, and across a variety of
patient and lesion subgroups, the 2 treatments yielded similar
composite endpoint results, including the presence of diabetes
mellitus, acute coronary syndrome, complex lesions, and
multivessel disease.
Rates of cardiac mortality, myocardial infarction, and
target vessel revascularization did not differ significantly
Figure 1. Trial flow diagram.
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between the 2 groups, although definite stent thrombosis was
lower in the everolimus-eluting stent group.
Increased risk of late and very late stent thrombosis
associated with first-generation drug-eluting stents led to
recommendations for large-scale randomized clinical end-
point trials encompassing a variety of patient categories and
types of coronary lesions to allow a head-to-head comparison
of drug-eluting stents with different stent platforms, poly-
mers, and antiproliferative drugs. Extensive comparisons of
sirolimus-eluting and paclitaxel-eluting stents demonstrated
similar safety and probably higher efficacy for the sirolimus-
eluting stent.19,21–23 A number of second-generation drug-
eluting stents have been developed, aiming to achieve reste-
nosis rates similar to those of sirolimus-eluting and
paclitaxel-eluting stents but with a better safety profile.
Although the zotarolimus-eluting Endeavor stent did not
reach the efficacy level of the sirolimus-eluting stent and
showed no indication of improved safety,6 the everolimus-
eluting stent seemed promising in terms of both safety and
efficacy. The Second-Generation Everolimus-Eluting and
Paclitaxel-Eluting Stents in Real-Life Practice (COMPARE)
trial7 and the Everolimus-Eluting Versus Paclitaxel-Eluting
Stents in Coronary Artery Disease (SPIRIT IV) trial24 com-
paring everolimus-eluting and paclitaxel-eluting stents
showed a favorable safety and efficacy profile for the
everolimus-eluting stent. In the SPIRIT V trial,24 the
everolimus-eluting stent demonstrated lower rates of target
vessel failure; in the COMPARE trial,7 it demonstrated a
reduced rate of combined all-cause mortality, nonfatal myo-
cardial infarction, target vessel revascularization, and early
definite stent thrombosis compared with paclitaxel-eluting
Table 2. Baseline Characteristics of the Study Population
Everolimus-
Eluting Stent
(n1390),
n (%)
Sirolimus-
Eluting Stent
(n1384),
n (%) P
Age, mean (SD), y 64.2 (10.9) 64.0 (10.8) 0.68
Men 1055 (75.9) 1041 (75.2) 0.68
Diabetes mellitus 194/1390 (14.0) 196/1384 (14.2) 0.88
Arterial hypertension 689/1215 (56.7) 649/1207 (53.8) 0.15
Hypercholesterolemia 866/1218 (71.1) 859/1208 (71.1) 1.00
Current smoker 344/1178 (29.2) 353/1162 (30.4) 0.53
Body mass index, mean
(SD), kg/m2
27.5 (4.7) 27.4 (4.4) 0.43
Previous myocardial
infarction
276/1223 (22.6) 259/1214 (21.3) 0.46
Previous percutaneous
coronary intervention
264/1227 (21.5) 250/1214 (20.6) 0.58
Previous coronary artery
bypass grafting
118/1227 (9.6) 97/1214 (8.0) 0.16
Indication for percutaneous
coronary intervention
0.46
ST-segment–elevation
myocardial infarction
122 (8.8) 145 (10.5)
Non–ST-segment–
elevation myocardial
infarction or unstable
angina
458 (32.9) 453 (32.7)
Stable angina 773 (55.6) 754 (54.4)
Other 37 (2.7) 32 (2.3)
Table 3. Baseline Lesion and Procedure Characteristics
Everolimus-
Eluting Stent
(n1390)
Sirolimus-
Eluting Stent
(n1384) P
Lesions, n 1805 1779
Target lesions per patient,
n (%)
0.85
1 1062 (76.4) 1072 (77.5)
2 256 (18.4) 244 (17.6)
3 60 (4.3) 54 (3.9)
3 12 (0.9) 14 (1.0)
Per patient, n 1.3 (0.6) 1.3 (0.6) 0.56
Target vessel location, n (%) 0.08
Left main artery 37 (2.0) 25 (1.4)
Left anterior descending
artery
738 (40.9) 805 (45.3)
Left circumflex artery 434 (24.0) 397 (22.3)
Right artery 581 (32.2) 537 (30.2)
Saphenous vein graft 15 (0.8) 15 (0.8)
Lesion type, n (%) 0.57
A 287 (15.9) 265 (14.9)
B1 489 (27.1) 499 (28.0)
B2 351 (19.4) 324 (18.2)
C 678 (37.6) 691 (38.8)
Chronic total occlusion
lesions, n (%)
111 (6.4) 105 (6.1) 0.78
Bifurcation lesions, n (%) 215 (12.3) 217 (12.7) 0.76
Lesion length 18 mm,
n (%)
557 (30.9) 528 (29.7) 0.44
Lesion length, mm
Mean 16.5 (11.0) 16.9 (12.0) 0.32
Range 0.0–90.0 2.0–120.0
Reference vessel size,
median (range), mm
3.2 (3.0–3.6) 3.2 (3.0–3.5) 0.06
Stents, n
Per patient 1.6 (1.0) 1.6 (0.9) 0.21
Per lesion 1.3 (0.6) 1.2 (0.6) 0.26
Total stent length, mm
Per patient 26.4 (17.5) 26.6 (18.2) 0.78
Per lesion 20.3 (12.3) 20.7 (12.9) 0.38
Direct stenting, n (%) 403 (22.4) 361 (20.4) 0.14
Stent delivery failure, n (%) 53 (2.9) 36 (2.0) 0.08
Maximum pressure, atm 16.4 (4.2) 17.6 (4.2) 0.001
Length of procedure, min 27.3 (20.0) 27.9 (20.6) 0.45
Fluoroscopy time, min 9.2 (8.6) 9.7 (9.2) 0.13
Contrast, mL 121.5 (85.5) 124.1 (87.3) 0.42
Use of glycoprotein IIb/IIIa
inhibitors, n (%)
213 (15.3) 234 (16.9) 0.26
Data are mean (SD), number of patients (%), or median (interquartile range)
as appropriate.
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Table 4. Clinical Outcomes
Everolimus-Eluting
Stent (n1390),
n Patients (%)
Sirolimus-Eluting
Stent (n1384),
n Patients (%)
Hazard Ratio* (95%
Confidence Interval) P†
Events at 30 d
Death
All-cause mortality 12 (0.9) 9 (0.7) 1.33 (0.56–3.15) 0.52
Cardiac 12 (0.9) 9 (0.7) 1.33 (0.56–3.15) 0.52
Noncardiac 0 0 . . . . . .
Myocardial infarction 7 (0.5) 9 (0.7) 0.77 (0.29–2.08) 0.61
Target vessel revascularization 13 (0.9) 16 (1.2) 0.81 (0.39–1.68) 0.57
Target lesion revascularization 9 (0.6) 9 (0.7) 1.00 (0.40–2.51) 0.99
Events at 9 mo
Composite end point‡ 68 (4.9) 72 (5.2) 0.94 (0.67–1.31) 0.71
Death
All-cause mortality 36 (2.6) 27 (2.0) 1.33 (0.81–2.19) 0.26
Cardiac 27 (1.9) 20 (1.4) 1.35 (0.76–2.40) 0.31
Noncardiac 9 (0.6) 7 (0.5) 1.29 (0.48–3.46) 0.62
Myocardial infarction 15 (1.1) 19 (1.4) 0.79 (0.40–1.55) 0.48
Stent thrombosis†
Definite 2 (0.1) 9 (0.7) 0.22 (0.05–1.02) 0.05
Acute (24 h) 0 (0.0) 3 (0.2) . . . . . .
Subacute (24 h–30 d) 2 (0.1) 4 (0.3) 0.50 (0.09–2.71) 0.42
Late (30 d) 0 (0.0) 2 (0.1) . . . . . .
Probable 7 (0.7) 4 (0.3) 1.74 (0.51–5.96) 0.38
Definite or probable 9 (0.9) 13 (0.9) 0.69 (0.29–1.61) 0.39
Possible 9 (0.7) 5 (0.4) 1.80 (0.60–5.37) 0.29
Definite, probable, or possible 18 (1.5) 18 (1.3) 1.00 (0.52–1.91) 0.99
Target vessel revascularization 39 (2.8) 48 (3.5) 0.81 (0.53–1.23) 0.32
Target lesion revascularization 20 (1.4) 23 (1.7) 0.87 (0.48–1.58) 0.64
Events at 18 mo
Composite end point 99 (7.2) 105 (7.6) 0.94 (0.71–1.23) 0.64
Death
All-cause mortality 56 (4.0) 51 (3.7) 1.10 (0.75–1.60) 0.63
Cardiac 28 (2.0) 22 (1.6) 1.27 (0.73–2.22) 0.40
Noncardiac 28 (2.1) 29 (2.1) 0.97 (0.57–1.62) 0.89
Myocardial infarction 22 (1.6) 25 (1.8) 0.87 (0.49–1.55) 0.65
Stent thrombosis§
Definite 3 (0.2) 12 (0.9) 0.25 (0.07–0.88) 0.03
Acute (24 h) 0 (0.0) 3 (0.2) . . . . . .
Subacute (24 h–30 d) 2 (0.1) 4 (0.3) 0.50 (0.09–2.71) 0.42
Late (30 d–12 mo) 0 (0.0) 2 (0.1) . . . . . .
Very late (12 mo) 1 (0.1) 3 (0.2) 0.33 (0.03–3.17) 0.34
Probable 7 (0.5) 4 (0.3) 1.74 (0.51–5.96) 0.38
Definite or probable 10 (0.7) 16 (1.2) 0.62 (0.28–1.37) 0.24
Possible 10 (0.7) 5 (0.4) 2.00 (0.68–5.88) 0.21
Definite, probable, or possible 20 (1.4) 21 (1.5) 0.95 (0.51–1.75) 0.86
Target vessel revascularization 67 (4.8) 77 (5.6) 0.86 (0.62–1.20) 0.38
Target lesion revascularization 36 (2.6) 45 (3.3) 0.80 (0.51–1.23) 0.30
*From a Cox regression model.
†Two-sided from a Cox regression model.
‡Primary end point. Composite of major adverse cardiac events: cardiac death, myocardial infarction, definite stent
thrombosis, and clinically driven target vessel revascularization.
§Academic Research Consortium definition.
Okkels Jensen et al Everolimus-Eluting Versus Sirolimus-Eluting Stents 1251
 by guest on January 16, 2017
http://circ.ahajournals.org/
D
ow
nloaded from
 
stents. A comparison showed similar rates of target lesion
failure in the zotarolimus-eluting Endeavor Resolute stent
and the everolimus-eluting stent but a higher rate of definite
stent thrombosis in the Resolute stent within the first 12
months.9 These results were sustained after 24 months;
however, the numbers of very late definite stent thromboses
were equal in the 2 groups.25 A positive safety profile for the
everolimus-eluting stent also emerged in long-term registry-
Figure 2. Time-to-event curves for major adverse cardiac events. Major adverse cardiac events are a composite of cardiac death, myo-
cardial infarction, definite stent thrombosis, and target vessel revascularization. A, Major adverse cardiac events. B, Cardiac death. C,
Myocardial infarction. D, Target vessel revascularization. E, Definite stent thrombosis. F, Definite or probable stent thrombosis.
Figure 3. Prespecified subgroup analysis for the primary end point at the 18-month follow-up. Data are presented by number of
patients. Major adverse cardiac events are a composite of cardiac death, myocardial infarction, definite stent thrombosis, and target
vessel revascularization. CI indicates confidence interval; LAD, left anterior descending artery; PCI, percutaneous coronary intervention;
and STEMI, ST-segment–elevation myocardial infarction.
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based follow-up studies and in the SPIRIT I through III
studies.8,26–28
Surprisingly, our study showed a significant association
with less definite stent thrombosis in patients treated with the
everolimus-eluting stent. This finding also was observed in
the Comparison of Zotarolimus-Eluting and Everolimus-
Eluting Coronary Stents (RESOLUTE) trial9 in which the
everolimus-eluting stent was associated with significantly
less definite stent thrombosis than the zotarolimus-eluting
Endeavor Resolute stent. The low rates of definite stent
thrombosis observed in the present trial also were comparable
to those in the everolimus-eluting groups in 3 large random-
ized trials: COMPARE,7 RESOLUTE,9 and SPIRIT IV,24 in
which the rates after 12 months were 0.4%, 0.3%, and 0.3%,
respectively, according to the ARC definition.15 The favor-
able stent thrombosis rate for the everolimus-eluting stent
awaits confirmation in longer-term follow-up randomized
studies. The definite stent thrombosis results were a second-
ary end point that should be interpreted with caution and need
replication to confirm that they are not spurious. A registry
cohort study that compared the long-term performance of
everolimus-eluting and sirolimus-eluting stents using propen-
sity score matching found that definite stent thrombosis was
less frequent among patients treated with everolimus-eluting
stents.29 For the sirolimus-eluting stent group, the definite
stent thrombosis rate observed in our trial was comparable to
that for the sirolimus-eluting stent in other all-comer
studies.6,19
Definite stent thrombosis is documented most often
through catheterization because autopsies are rare. Although
the definite stent thrombosis definition maximizes specificity,
it may be insufficiently sensitive to capture completely this
relatively rare event. Sensitivity can be increased by includ-
ing cases of probable and possible stent thrombosis in the
analysis. In accordance with the ARC recommendation,15 we
combined adjudicated definite and probable stent thrombosis
events to obtain the best safety characterization of the 2 stents
under investigation. We found that the combined definite or
probable stent thrombosis rates in the 2 stent groups were
equal.
Target vessel revascularization and target lesion revascu-
larization were low in both groups but comparable to previ-
ous studies without angiographic follow-up.6,7,19 We found a
slightly lower reintervention rate in our everolimus-eluting
stent group compared with the RESOLUTE trial,25 most
likely because of the 18-month follow-up interval in our
study and the 24-month follow-up interval in the RESOLUTE
trial. We also found a slightly lower reintervention rate in our
sirolimus group compared with that in the Biolimus-Eluting
Stent With Biodegradable Polymer Versus Sirolimus-Eluting
Stent With Durable Polymer for Coronary Revascularization
(LEADERS) trial.30 The Intracoronary Stenting and Angio-
graphic Results: Test Efficacy of 3 Limus-Eluting Stents
(ISAR-TEST-4) trial,31 which compared the everolimus-
eluting stent and the sirolimus-eluting stent, found no differ-
ence in performance efficacy between the 2 stent groups
within 12 months. That trial included a scheduled angiogra-
phy after 6 to 8 months, resulting in higher target vessel
revascularization rates compared with our study, which, like
the earlier SORT OUT studies, relied on detection of clini-
cally driven events from medical registries to avoid study-
induced reinterventions.32
The SORT OUT II,19 III,6 and IV studies relied on
registry-based event detection without study-related angio-
graphic or clinical follow-up. Patient care complied with
normal clinical practice, ie, follow-up during a hospital
outpatient visit after 1 to 3 months. We believe that this
approach to event detection, combined with a randomized
all-comer trial design, allowed us to assess the efficacy of
different percutaneous coronary interventions in a context
reflecting everyday clinical practice during the study period.
Our findings showed fewer events, particularly fewer myo-
cardial infarctions, than reported in other randomized tri-
als.7,9,30 This difference can be explained partly by procedure-
related myocardial infarction, which was not part of the
primary end point in the SORT OUT IV trial. In the
LEADERS trial,30 the myocardial infarction rate increased
0.5% and 0.6%, respectively, from 30 days (biolimus-eluting
stent, 4.9%; sirolimus-eluting stent, 4.1%) to 9 months after
implantation (biolimus-eluting stent, 5.7%; sirolimus-eluting
stent, 4.6%), indicating that the majority of myocardial
infarctions were early and related predominantly to stent
implantation. It is important to note that our follow-up period
of 18 months may be too short to assess the risk of very late
stent thrombosis.
Like most stent trials, the SORT OUT IV trial was
designed as a single-blind study, and we believe that the lack
of double-blindness would not influence the results because
all end points were objective and determined by event
committee members who were blinded to treatment group
assignment during the adjudication process. There was a
lower rate of major adverse cardiac events in both treatment
groups than assumed in the power calculation. At the time the
study was designed, most randomized trials had on-label
indications for enrollment, and the true rate of major adverse
cardiac events was not available in the literature. In particu-
lar, there were no data on the clinically driven event rate. The
clinical outcomes after implantation of drug-eluting stents
have improved in recent years. Therefore, we expect that the
event rate in our study is representative of the real event rate
among this patient population.
Conclusion
The everolimus-eluting stent was found to be noninferior to
the sirolimus-eluting stent for patients treated with percuta-
neous coronary intervention.
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CLINICAL PERSPECTIVE
Among drug-eluting stents released to date, the sirolimus-eluting stent has demonstrated the least amount of late lumen
loss, but its efficacy and safety have not been compared head-to-head with the next-generation everolimus-eluting stent.
The Scandinavian Organization for Randomized Trials with Clinical Outcome IV (SORT OUT IV) trial compared the
everolimus-eluting stent with the sirolimus-eluting stent in patients with coronary artery disease. The primary end point was
a composite of safety (cardiac death, myocardial infarction, definite stent thrombosis) and efficacy (target vessel
revascularization) parameters. A total of 1390 patients were assigned to receive the everolimus-eluting stent and 1384
patients to the sirolimus-eluting stent. At the 9-month follow-up, 4.9% of the patients treated with the everolimus-eluting
stent compared with 5.2% of the patients treated with the sirolimus-eluting stent experienced the primary end point (P for
noninferiority0.01). At the 18-month follow-up, this difference remained. The rate of definite stent thrombosis was
higher in the sirolimus-eluting group compared with the everolimus-eluting group (0.9% versus 0.2%). The everolimus-
eluting stent was found to be noninferior to the sirolimus-eluting stent.
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Correction
e158
In the article by Jensen et al, “Randomized Comparison of Everolimus-Eluting and Sirolimus-
Eluting Stents in Patients Treated With Percutaneous Coronary Intervention: The Scandinavian 
Organization for Randomized Trials With Clinical Outcome IV (SORT OUT IV)’,” which pub-
lished in the March 13, 2012 issue of the journal (Circulation. 2012;125:1246–1255), a collabo-
rator’s name was spelled incorrectly. The collaborating author’s name should be Bjarne Linde 
Norgaard MD, PhD instead of Bjarne Linde Noergaard MD, PhD.
The current online-only Data Supplement has been corrected.
(Circulation. 2013;128:e158.)
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